Contact

Daria Pašalić
Editor-in-Chief
Department of Medical Chemistry, Biochemistry and Clinical Chemistry
Zagreb University School of Medicine
Šalata ul 2.
10 000 Zagreb, Croatia
Phone +385 (1) 4590 205; +385 (1) 4566 940
E-mail: dariapasalic [at] gmail [dot] com

Useful links

Plenary lectures

 

Stavljenić-Rukavina A. PL2-1: The impact of laboratory technological innovations on efficacy in health care.Biochemia Medica 2009;19(Suppl 1):S10.
Croatian Chamber of Medical Biochemists, Zagreb, Croatia
*Corresponding author: astavljenic [at] hkmb [dot] hr
 
Abstract
 
The variety of new technology both in health care and society asks for critical assessment of efficacy and safety. This is particularly important in a view of changes in health system and overall need for more efficacy and evidence based application of new either diagnostic tests or innovative drugs. This overview is focused on technologies for POC and efficient use of potent new drugs in oncology based on laboratory testing.
The changes in organization of health system, tendency for lowering hospital care in favor of day care, home care of chronic diseases, continuity of care between hospital and home care, requires good communication between physician, patient and family. The advance in POC, non invasive control of some important analytes in human body has an essential role in home care, but requires the education of patients in application and quality control of diagnostic tests.
Today’s treatments for cancer, namely the molecularly-targeted anti-cancer therapies are a vas improvement on treatments of ten years ago. However, the therapies do not work for everyone, at least not as effective and a test to determine the efficacy of these drugs in a patient could be the first crucial step in personalizing treatment to the individual. Additionally, most patients today are treated not with a targeted therapy drug alone but with a combination of chemotherapy drugs. Therefore existing DNA and RNA tests do not reflect the way cancer medicine in practiced today. Therefore the development of whole cell profiling method differs from other tests in that it assesses the activity of drug upon combined effect of all cellular processes using several metabolic and morphological end points. New DNA, RNA and protein-based tests are predictive ones and evaluated according evidence based principles might serve as gold standard model. Patients, physicians and health insurance welcomed predictive tests that allow for rational and cost-effective use of drugs. Simultaneously this whole cell approach might solve the problems confronting the healthcare system efficacy that is seeking ways to best allocate available resources while accomplishing the critical tasks of matching individual patients with the treatments most likely to benefit them.